Addressing Patients at High Risk for SCA

Slides:

Advertisements

Similar presentations

INTRINSIC RV Trial Presented at The Heart Rhythm Society Meeting May 2006 Presented by Dr. Brian Olshansky Inhibition of Unnecessary RV Pacing with AV.

Advertisements

Presenter Disclosure Information

Primary Prevention ICD Therapy: Tools to Enhance Guideline Compliance By: Margaret S. Thomas, RN,CVRN Michael J. Mirro, MD Alicia S. Floor, AS,RN, Rob.

ICD FOR PRIMARY PREVENTION EVIDENCE REVIEW

Prognostic Value of Programmed Electrical Stimulation Among Implantable Cardioverter-Defibrillator Recipients Real-World Data from the Israeli National.

VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.

HPS: Heart Protection Study Purpose To determine whether simvastatin reduces mortality and vascular events in patients with and without coronary disease,

WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.

IRIS Post-hoc Analysis Background IRIS compared the safety and efficacy of early ICD implantation with medical treatment alone in 898 patients at high.

4S: Scandinavian Simvastatin Survival Study

Charmaine J. Palafox, MD. Approx. 50% of CHD deaths occurs as sudden cardiac arrest.

European trial on reduction of cardiac events with perindopril in stable coronary artery disease Presented at European Society of Cardiology 2003 EUROPA.

Date of download: 6/25/2016 Copyright © The American College of Cardiology. All rights reserved. From: Indications for Implantable Cardioverter-Defibrillators.

Wearable Cardioverter Defibrillators

Sudden Cardiac Arrest Morhaf Ibrahim, MD, FHRS Electrophysiology.

Implantable Defibrillator Therapy Post Cardiac Arrest

Wearable cardioverter-defibrillator for prevention of sudden cardiac death after infected implantable cardioverter-defibrillator removal: A cost-effectiveness.

Defibrillator in Acute Myocardial Infarction Trial

Addressing the Challenges in Primary and Secondary Stroke Prevention

Figure 1 Study flow chart.

The European Society of Cardiology Presented by Dr. Bo Lagerqvist

Patient populations by study group figure 10

HOPE: Heart Outcomes Prevention Evaluation study

Trends in Coronary Procedures per 1000 Medicare Beneficiaries

New Guidelines to Prevent SCD: What You Need to Know

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons From Clinical Trials.

Managing Bleeds in Patients Anticoagulated With Warfarin and Other Agents.

CathPCI-NCDR Registry Mortality (STEMI)

Know Your ABCs: Antiplatelet Therapy, Benefits/Bleeding, and Cardiac Surgery State of the Art: The Role of Antiplatelet Therapy in the Cardiac Surgical.

Risk Stratification in PAH: What Do the Latest Data Suggest?

Preventing SCD With a WCD: Reviewing the Results of the VEST Trial

Unmet Needs in the Secondary Prevention in ACS

Select Topics in Cardiovascular Medicine

Patient Presentation Patient’s Changing Condition Multiple Considerations To Balance.

It’s Elementary.

What Has Been Tried and What Is True?

How and When to Decide on Revascularization in Stable Ischemic Heart Disease.

Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.

Clarifying Optimal Patient Selection for Long-Term DAPT Post-MI

NOAC Use in AF: REAL-WORLD Studies WITH REAL RESULTS

Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.

MASTER Trial Inclusion Criteria

Personalizing Statin Therapy in Patients With HIV

Understanding PAD.

Reversal Strategies for VKA: Truths and Misconceptions

Risk Stratification in CAD and PAD

Remote Patient Management:

CV Risk Management in T2DM: What Did We Learn from ADA 2016?

Aspirin and Cardioprevention in 2018

Panelists. Cardiovascular Risk Modulation in Diabetes: Emerging Pathways and Insights.

Managing Age-Related Clinical Issues in Hemophilia

Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.

Elevated Admission Plasma Glucose Following ACS

Practical Tools for SCA Screening

Disease Burden of VTE Phases of VTE Treatment.

2015 EASD In Review: CV Risk management in t2dm

Volume 11, Issue 3, Pages (March 2014)

The Heart Rhythm Society Meeting Presented by Dr. Johan De Sutter

Addressing Cardiovascular Events:

Volume 8, Issue 3, Pages (March 2011)

Figure 1 Distribution of WCD use days in WEARIT-II

Lipids, the Heart, and the Kidney

BRIDGING CVD AND T2DM: LESSONS LEARNED FROM OUTCOME TRIALS

Rethinking Risk Stratification for Nonischemic HF:

Figure 9.1.a Causes of death in ESRD patients,

(A). (A). Kaplan-Meier plot of event-free survival in 27 LMNA mutation carriers and 78 DCM control patients. Death, heart transplantation, resuscitation.

The Power of As-Treated Analyses

Translating Data From Trial to Practice

Presentation transcript:

Addressing Patients at High Risk for SCA

Learning Objectives

Burden of CVD and Risk of SCD

Heart Rhythm Society SCD Primary Prevention Protocols

VALIANT Study

DINAMIT

IRIS

LifeVest® Wearable Cardioverter Defibrillator (WCD)

WEARIT-II Characteristics of Patients

WEARIT-II Arrhythmic Events Total Population (Median Wear Time 90 days)

WEARIT-II Safety Endpoints

WEARIT-II Arrhythmic Events Total Population (Median Wear Time 90 days)

Arrhythmic Events WEARIT-II vs MADIT-RIT

WCD Use Early After Coronary Revascularization (CR)

WEARIT-II Registry Probability of One-Year Mortality

Congenital, Inherited Heart Disease

Indications for WCD Use Bridging Period for ICD or Heart Transplantation

Recommendations for WCD Use Risk Stratification

LifeVest® Network

Summary

Abbreviations

Abbreviations (cont)